...
首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation
【24h】

Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation

机译:INT 0144试验的药理学分析:5-FU和放射治疗的直肠癌患者多态性与生存率和毒性的关系

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Purpose: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy.
机译:目的:我们测试了16个基因(GSTP1,COX2,IL10,EGFR,EGF,FGFR4,CCDN1,VEGFR2,VEGF,CXCR2,IL8,MMP3,ICAM1,ERCC1,RAD51和XRCC3)中的18个多态性是否可以预测无病生存(DFS),总生存期(OS)和毒性试验在INT0144试验中进行,该试验旨在研究局部晚期直肠癌中基于5氟尿嘧啶(5-FU)的化学放射(CRT)的不同术后治疗方案:第1臂由推注5-FU,然后进行5-FU持续静脉输注(PVI)并进行放射治疗;第2组为放疗诱导和伴随PVI 5-FU,第3组为放疗诱导和伴随推注5-FU。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号